Pirfenidone is under clinical development by Avalyn Pharma and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pirfenidone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pirfenidone (GP-101) is under development for the treatment of interstitial lung fibrosis , idiopathic pulmonary fibrosis (IPF) and chronic lung allograft dysfunction. It is an aerosol formulation administered through inhalation route for direct delivery to the lungs. The drug candidate is a small synthetic non-peptide molecule with both anti-inflammatory and anti-fibrotic activities.
Avalyn Pharma overview
Avalyn Pharma is a biopharma company which focuses on advanced therapies for the treatment of Idiopathic Pulmonary Fibrosis. Avalyn Pharma is headquartered in Seattle, Washington, the US.
For a complete picture of Pirfenidone’s drug-specific PTSR and LoA scores, buy the report here.